Patricia Pozo Rosich, EAN 2018 – Erenumab for the prevention of migraine
Patricia Pozo Rosich (Headache Unit and Headache Research Group, Vall d’Hebron University Hospital, Barcelona, Spain) talks to us about unmet needs of migraine prevention in Europe and the calcitonin gene-related peptide receptor antagonist, erenumab, in light of it recently receiving a positive CHMP opinion for this indication.
Questions
1. What are the major unmet needs of migraine prevention in Europe? (0:12)
2. What is the mechanism of action of erenumab? (0:50)
3. How is erenumab administered? (1:44)
4. Could you tell us a little about the evidence base for the positive CHMP opinion for erenumab for the prevention of migraine? (2:08)
5. Which patients are most likely to benefit from erenumab? (2:39)
Speaker disclosure: Patricia Pozo Rosich serves as a speaker/adviser for Allergan, Almirall, Chiesi, Novartis, Teva and Lilly; she also receives grant support from Allergan.
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
